Achieve full patient enrollment in the first cohort of the AMT-130 clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 5 Apr 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“uniQure expects to achieve full patient enrollment in cohort one by mid-year 2021.”
What we found
Evidence strength A What the grades mean
The company announced the completion of enrollment for the first dose cohort of the AMT-130 clinical trial on April 5, 2021, which is before the mid-year 2021 deadline.
-
A uniQure N.V. 10-Q filed 2021-10-25
“On April 5, 2021, we announced the completion of enrollment of all 10 patients in the first dose cohort of our Phase I/II clinical trial of AMT-130.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +549 days
- 2 versions
-
Version 1 · original · stated 9 Feb 2021
Deadline 30 Jun 2021 (“mid-year 2021”) · wording expected
-
Version 2 · stated 8 Feb 2022
Deadline 31 Dec 2022 (“by the end of the year”) · wording expected
“We expect to complete patient enrollment in this European study by the end of the year”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Achieve
- Deliverable
- Full patient enrollment in cohort one
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-023328 · Corrections policy